Skip to main content
. 2021 Jun 11;27(16):4599–4609. doi: 10.1158/1078-0432.CCR-21-0205

Figure 3.

Figure 3. RNA expression–based immune score differs among UROMOL subclasses and is associated with RFS after BCG. A, Average expression counts for markers of various immune cell types for each patient. B–E, RFS by immune score in the entire MSK cohort (B); MSK patients treated with BCG (C); entire UROMOL cohort (D), UROMOL patients treated with BCG (E).

RNA expression–based immune score differs among UROMOL subclasses and is associated with RFS after BCG. A, Average expression counts for markers of various immune cell types for each patient. B–E, RFS by immune score in the entire MSK cohort (B); MSK patients treated with BCG (C); entire UROMOL cohort (D), UROMOL patients treated with BCG (E).